In this context of conflicting results, two large randomized trials are under way: the PROWESS-SHOCK (Protein C Worldwide Evaluation in Severe Sepsis-Shock ) trial is evaluating the efficacy and safety of drotrecoginalfa in adult patients with septic shock (clinical trials number NCT00604214), and the APROCCHS (Activated Protein C and Corticosteroids for Human Septic Shock) study is evaluating the efficacy and interactions of rhAPC and corticosteroids in septic shock.